Author

Muhammed Favas KT

Observed names: K.T. Muhammed Favas, KT Muhammed Favas, Muhammed Favas K. T, Muhammed Favas Karimbanathottathil

Institutions: National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research

Observed institutions: National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, Saveetha University

ORCID: 0000-0001-8068-6839

Observed ORCID: 0000-0001-8068-6839

OpenAlex ID: A5035988280

Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis

2024 · Beema T Yoosuf, Abhilash Kumar Panda, et al. · Scientific Reports · 29

Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: A meta-analysis of randomised controlled trials and disproportionality analysis using FAERS

2025 · Beema T Yoosuf, Muhammed Favas KT, et al. · Endocrine · 24

The Possible Role of Selected Vitamins and Minerals in the Therapeutic Outcomes of Leishmaniasis

2022 · V Udaya kumar, Muhammed Favas KT, et al. · Biological Trace Element Research · 18

Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS

2024 · Muhammed Favas KT, Maneesh Semwal, et al. · Annals of Hematology · 10

Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms

2024 · Beema T Yoosuf, Muhammed Favas KT, et al. · Expert Opinion on Drug Safety · 9

Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials

2024 · Muhammed Favas Karimbanathottathil, Beema T Yoosuf, et al. · Scientific Reports · 8

Insights into the systemic risk factors associated with diabetic retinopathy in the Indian population: A comprehensive systematic review and meta-analysis

2024 · KT Muhammed Favas, Mamidi Niveditha, et al. · Indian Journal of Ophthalmology · 6

Cardiac Adverse Events Associated With Elotuzumab: A Disproportionality Analysis Using FDA Adverse Event Reporting System

2025 · Muhammed Favas K. T, Beema T. Yoosuf, et al. · Annals of Pharmacotherapy · 1

Critical evaluation of endotoxin contamination in intravenous solutions: A call for enhanced regulatory oversight and quality control

2024 · K.T. Muhammed Favas, Guru Datt Sharma, et al. · Clinical Infection in Practice · 1

Author Correction: Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis

2024 · Beema T Yoosuf, Abhilash Kumar Panda, et al. · Scientific Reports · 1

Development and Psychometric Validation of Nu-KAP Questionnaire: Integrating IRT and Multigroup Factor Analysis in a Multidimensional Tool for the Assessment of Knowledge, Attitudes, and Practices of Arsenic

2025 · V. Udaya Kumar, K. Nikhil, et al. · Biological Trace Element Research

Safety Profile of Istradefylline in Parkinson’s Disease: A Meta-Analysis of Randomized Controlled Trials and Disproportionality Analysis Using FAERS

2025 · Beema T Yoosuf, Suhani Jain, et al. · Journal of Geriatric Psychiatry and Neurology

Navigating the Impact of India's Recent Ban on Fixed-Dose Combinations: A Call for Evidence-Based Regulation

2024 · Muhammed Favas KT, Guru Datt Sharma, et al. · Advanced Pharmaceutical Bulletin

Works count: 13

Citation count: 107

H-index: 6

I10-index: 4